| Literature DB >> 32563014 |
Antonin Levy1, Anna D Wagner2, Cyrus Chargari3, Markus Moehler4, Marcel Verheij5, Jérôme Durand-Labrunie6, Manon Kissel6, Erick Chirat6, Pascal Burtin7, Michel Ducreux8, Valérie Boige7, Magnus Nilsson9, Narikazu Boku10, Ian Chau11, Eric Deutsch3.
Abstract
Malignant dysphagia is the most common symptom in advanced oesogastric cancers patients. Relief of dysphagia allows quality of life improvement, nutritional replenishment and potentially improves prognosis. Chemotherapy alone is effective and should be prioritised in patients with metastatic disease a good performance status, and its impact on dysphagia should be determined before further interventions are planned. Regarding local treatments, the insertion of a covered self-expandable metallic stent is the most commonly used alternative, as it allows for the rapid relief of severe dysphagia. Although several randomised trials have highlighted the role of oesophageal brachytherapy, this technique is often not easily accessible. Contemporary trials are ongoing to better define the role of external radiation therapy. While awaiting these results, external radiation therapy can be considered as a second-best option for patients with a life-expectancy > 3 months. It is important to offer nutritional support and to integrate quality of life measures in the palliative management of dysphagia. This multidisciplinary international position paper aims to propose a decision-making process and highlight randomised trials for the management of malignant dysphagia in metastatic oesogastric cancer patients.Entities:
Keywords: Consensus; Quality of life; Supportive care; Upper gastrointestinal cancer
Mesh:
Substances:
Year: 2020 PMID: 32563014 DOI: 10.1016/j.ejca.2020.04.032
Source DB: PubMed Journal: Eur J Cancer ISSN: 0959-8049 Impact factor: 9.162